These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29856019)

  • 21. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HttQ111/+ Huntington's Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction.
    Kovalenko M; Milnerwood A; Giordano J; St Claire J; Guide JR; Stromberg M; Gillis T; Sapp E; DiFiglia M; MacDonald ME; Carroll JB; Lee JM; Tappan S; Raymond L; Wheeler VC
    J Huntingtons Dis; 2018; 7(1):17-33. PubMed ID: 29480209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum.
    Chen CM; Wu YR; Chang KH
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
    Kao YH; Lin MS; Chen CM; Wu YR; Chen HM; Lai HL; Chern Y; Lin CJ
    Hum Mol Genet; 2017 Feb; 26(3):467-478. PubMed ID: 28069792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease.
    Molero AE; Arteaga-Bracho EE; Chen CH; Gulinello M; Winchester ML; Pichamoorthy N; Gokhan S; Khodakhah K; Mehler MF
    Proc Natl Acad Sci U S A; 2016 May; 113(20):5736-41. PubMed ID: 27140644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
    Jeon J; Kim W; Jang J; Isacson O; Seo H
    Neuroscience; 2016 Jun; 324():20-8. PubMed ID: 26944602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
    Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
    BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treadmill exercise delays the onset of non-motor behaviors and striatal pathology in the CAG
    Stefanko DP; Shah VD; Yamasaki WK; Petzinger GM; Jakowec MW
    Neurobiol Dis; 2017 Sep; 105():15-32. PubMed ID: 28502806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.
    Tippett LJ; Waldvogel HJ; Snell RG; Vonsattel JP; Young AB; Faull RLM
    Adv Neurobiol; 2017; 15():129-161. PubMed ID: 28674980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-related and disease locus-specific mechanisms contribute to early remodelling of chromatin structure in Huntington's disease mice.
    Alcalá-Vida R; Seguin J; Lotz C; Molitor AM; Irastorza-Azcarate I; Awada A; Karasu N; Bombardier A; Cosquer B; Skarmeta JLG; Cassel JC; Boutillier AL; Sexton T; Merienne K
    Nat Commun; 2021 Jan; 12(1):364. PubMed ID: 33441541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
    Kolodziejczyk K; Raymond LA
    Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice.
    Rothe T; Deliano M; Wójtowicz AM; Dvorzhak A; Harnack D; Paul S; Vagner T; Melnick I; Stark H; Grantyn R
    Neuroscience; 2015 Dec; 311():519-38. PubMed ID: 26546830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
    Shekhar S; Vatsa N; Kumar V; Singh BK; Jamal I; Sharma A; Jana NR
    Hum Mol Genet; 2017 Jan; 26(2):420-429. PubMed ID: 28007908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.